The Food and Drug Administration on Friday approved Novo Nordisk's blockbuster weight loss drug Wegovy for use in slashing the risk of serious cardiovascular complications in adults with obesity ...

Novo Nordisk’s fast-growing weight loss med Wegovy just added a new cardiovascular FDA approval to its label, likely enabling the med's superstar status to reach new levels. The med is now the ...

Novo Nordisk A/S’s weight-loss shot Wegovy gained expanded clearance as a heart drug in the UK, as the country’s regulators followed the US in broadening use of the blockbuster medicine.

The U.K.’s health regulator on Tuesday approved the use of Novo Nordisk’s Wegovy drug to reduce the risk of obese adults suffering from serious heart problems or strokes.

The FDA's approval was based on a landmark phase three trial called SELECT. The study tested Wegovy in roughly 17,500 people with obesity and heart disease but who did not have diabetes.

Wegovy and its diabetes counterpart Ozempic sparked a weight loss industry gold rush over the past year for their ability to help patients shed pounds. That decision could widen insurance coverage ...

The Food and Drug Administration approved Novo Nordisk's blockbuster weight loss drug Wegovy for use in slashing the risk of serious cardiovascular complications in people with obesity and heart ...

The Food and Drug Administration approved Novo Nordisk's blockbuster weight loss drug Wegovy for use in slashing the risk of serious cardiovascular complications in people with obesity and heart ...

The FDA's approval was based on a landmark phase three trial called SELECT. The study tested Wegovy in roughly 17,500 people with obesity and heart disease but who did not have diabetes.

Wegovy and its diabetes counterpart Ozempic sparked a weight loss industry gold rush over the past year for their ability to help patients shed pounds. That decision could widen insurance coverage ...